Daily Ards Research Analysis
Three papers advance ARDS science across mechanism, diagnostics, and prognosis: endothelial lactate-driven lysine lactylation (K193) on ENO1 links glycolysis to CXCL12 production and endothelial dysfunction; plasma cell-free DNA methylomics map tissue injury patterns in pediatric ARDS; and a prospective cohort identifies plasma phenylalanine and phenylalanine/tyrosine ratio as early predictors of hospital mortality.
Summary
Three papers advance ARDS science across mechanism, diagnostics, and prognosis: endothelial lactate-driven lysine lactylation (K193) on ENO1 links glycolysis to CXCL12 production and endothelial dysfunction; plasma cell-free DNA methylomics map tissue injury patterns in pediatric ARDS; and a prospective cohort identifies plasma phenylalanine and phenylalanine/tyrosine ratio as early predictors of hospital mortality.
Research Themes
- Endothelial metabolic reprogramming and lysine lactylation in ARDS
- Precision diagnostics using cfDNA methylomics in pediatric ARDS
- Metabolomic biomarkers for ARDS prognosis
Selected Articles
1. Global Lactylome Reveals Lactylation-Dependent Mechanisms Underlying CXC Motif Chemokine Ligand 12 Expression in Pulmonary Endothelium During Acute Respiratory Distress Syndrome.
Using quantitative lactylome profiling, the authors link lactate-induced lysine lactylation to pulmonary endothelial dysfunction in ARDS. Hyperlactylation of ENO1 at K193 releases translational repression of CXCL12 mRNA and enhances ENO1 enzymatic activity, amplifying glycolysis; inhibiting lactylation mitigated experimental ARDS.
Impact: This is a mechanistic advance identifying lysine lactylation of ENO1 as a nodal link between metabolic reprogramming and chemokine production in ARDS. It opens a druggable axis (lactate–Klac–CXCL12) for endothelial-targeted therapy.
Clinical Implications: Targeting lactate-induced lysine lactylation or ENO1–CXCL12 signaling may offer endothelial-protective therapies in ARDS, complementing ventilatory strategies.
Key Findings
- Pulmonary lactate levels in ARDS patients correlated with disease severity and prognosis.
- Lactate drove pulmonary endothelial cell dysfunction via lysine lactylation; inhibiting lactylation reduced experimental ARDS and chemokine release.
- Quantitative lactylomics identified ENO1 K193 hyperlactylation, which released CXCL12 mRNA from translational repression and increased ENO1 enzymatic activity, amplifying glycolysis.
Methodological Strengths
- Integrative approach combining patient lung analyses, in vitro endothelial assays, in vivo ARDS models, and quantitative lactylome profiling
- Site-specific post-translational modification mapping (ENO1 K193) with functional validation
Limitations
- Translational applicability to humans remains untested in interventional studies
- Potential off-target effects and feasibility of pharmacologic lactylation inhibition are not addressed
Future Directions: Develop selective modulators of lysine lactylation or ENO1–CXCL12 signaling and test endothelial-targeted strategies in preclinical ARDS models and early-phase trials.
Acute respiratory distress syndrome (ARDS) is a life-threatening condition affecting millions of people worldwide. The severity of ARDS is associated with the dysfunction of pulmonary endothelial cells (PECs). Metabolic reprogramming is characterized by enhanced glycolysis and lactate accumulation, which play a critical role in this process. Here, we showed that lactate levels in the lungs of patients with ARDS were associated with disease severity and prognosis. Lactate promoted PEC dysfunction and drove exp
2. Cell-free DNA methylomics identify tissue injury patterns in pediatric ARDS.
Plasma cfDNA methylation profiling can assign tissue-of-origin for injury in pediatric ARDS, enabling objective mapping of organ damage. This platform highlights actionable pathways to stratify patients and inform targeted therapies.
Impact: Introduces a precision-diagnostic approach that can deconvolute tissue injury in pediatric ARDS, a critical step toward phenotype-driven therapies.
Clinical Implications: cfDNA methylomics may guide risk stratification, monitoring of multi-organ involvement, and selection of targeted interventions in pediatric ARDS.
Key Findings
- Plasma cfDNA methylation signatures identify tissue injury patterns in children with severe lung injury/ARDS.
- This approach points to new therapeutic targets by revealing which tissues are affected.
Methodological Strengths
- Use of cfDNA methylation to infer tissue-of-origin, enabling noninvasive organ injury mapping
- Focus on pediatric ARDS, addressing a high-need population
Limitations
- Sample size and validation cohorts are not specified in the abstract
- Clinical utility and impact on outcomes require prospective interventional validation
Future Directions: Validate cfDNA methylome tissue-injury panels in multi-center pediatric ARDS cohorts and integrate with clinical endpoints to guide trials.
Plasma cell-free DNA can ientify what tissues are damaged in children with severe lung injury, allowing us to identify new avenues to target therapies.
3. Plasma phenylalanine is associated with hospital mortality in acute respiratory distress syndrome: a prospective metabolic profiling cohort study.
In 214 ICU patients (180 ARDS, 34 controls), plasma phenylalanine was higher in ARDS at days 1, 3, and 7, and higher in non-survivors throughout. Day-1 phenylalanine and phenylalanine/tyrosine ratio independently predicted in-hospital mortality; a threshold >125.3 μM had the best predictive value.
Impact: Provides a pragmatic, early metabolic biomarker that independently predicts mortality, supporting risk stratification in ARDS.
Clinical Implications: Early phenylalanine measurement could augment prognostic models, inform intensity of monitoring and resource allocation, and motivate trials of metabolic modulation.
Key Findings
- Plasma phenylalanine was higher in ARDS than ICU controls at days 1, 3, and 7.
- Non-survivors had persistently higher phenylalanine and phenylalanine/tyrosine ratios; day-1 levels independently associated with hospital mortality (adjusted OR 1.009, 95% CI 1.001–1.017).
- A day-1 phenylalanine threshold >125.3 μM had the best predictive value for in-hospital mortality (adjusted OR 4.825, 95% CI 1.324–17.583).
Methodological Strengths
- Prospective cohort with serial sampling at days 1, 3, and 7
- Multivariable analyses including adjusted ORs and evaluation of multiple mortality endpoints (28-, 60-, 90-day, and in-hospital)
Limitations
- Single-country study; external validation and generalizability remain to be established
- Observational design precludes causal inference; optimal thresholds need prospective validation
Future Directions: Validate phenylalanine-based risk stratification across diverse ARDS populations and test metabolic modulation strategies targeting aromatic amino acid pathways.
BACKGROUND: Phenylalanine accumulation is associated with inflammation, immune system activation, and oxidative stress-all of which are involved in the pathophysiology of acute respiratory distress syndrome (ARDS). This study evaluated the correlation between longitudinal changes in plasma phenylalanine levels and clinical outcomes in patients with ARDS. METHODS: This prospective observational cohort study conducted in Taiwan focused on plasma amino acid profiling in ARDS patients between February 2017 an